Back to search results

A Study of Eloralintide for Obesity or Overweight

This study is testing a drug called Eloralintide (LY3841136) to see how well it works and if it's safe for adults who have obesity or are overweight, but do not have type 2 diabetes. You might be able to join if you are 18 or older and have a Body Mass Index (BMI) of 30 or higher, or a BMI of 27 or higher with certain weight-related health issues like high blood pressure or sleep apnea. The main goal is to see how much your body weight changes from the start of the study to Week 64. The study is currently unclear about its recruitment status and plans to enroll 1980 participants.

Study design
This is an interventional study comparing Eloralintide to a placebo (an inactive substance) in nearly 2000 participants. The study has a main phase and an extension phase.
What's involved
Participation in the main phase of the study will last about 75 weeks. If you have prediabetes, you will continue in an extension phase for an additional 2 years.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for body weight change is measured at Week 64, indicating follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07321886

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Recruiting
PHASE3Ages 18+InterventionalTreatment
Eli Lilly and Company
~1,980 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:EloralintidePlacebo

At a glance

Recruiting sites
132 of 162 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent Change from Baseline in Body Weight
Measured over Baseline, Week 64

Conditions

Obesity
Overweight

Explore related trials

ObesityOverweight

Where it's being run

162 sites across 37 states
China14
Germany13
Australia11
Brazil11
Argentina10
India10
Canada9
Japan9

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
1-317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have Body Mass Index (BMI) at screening of the following:
30 kilogram per square meter (kg/m2) OR
27 kg/m2 with at least one of the following weight-related health conditions at screening:
high blood pressure
dyslipidemia
obstructive sleep apnea, or
heart disease
Have a stable body weight (\<5% body weight change) for 90 days prior to screening.
Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight

Exclusion

Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
Have type 1 diabetes or type 2 diabetes
Have had within 90 days prior to screening:
heart attack
stroke
coronary artery revascularization
unstable angina, or
hospitalization due to congestive heart failure
Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
Have taken medications or alternative remedies intended for weight loss within 90 days of screening

What this trial measures

  • Percent Change from Baseline in Body WeightBaseline, Week 64